top of page

Patients’ Experiences & Engagements Medical Device Guidances - USFDA

US FDA issued two medical devices (final guidance documents on January 26, 2022, to help sponsors better incorporate and capture patients’ experiences in medical device clinical studies.


The 1st guidance is "Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation" which describe principles that should be considered when using Patient-Reported Outcome (PRO) instruments in the evaluation of medical devices and provide recommendations about the importance of ensuring the measures are fit-for-purpose.


Click HERE to know more detailed information about this guideline.

The 2nd guideline is "Patient Engagement in the Design and Conduct of Medical Device Clinical Studies" which is intended

  1. To help sponsors understand how they can voluntarily use patient engagement to elicit experience, perspectives, and other relevant information from patient advisors to improve the design and conduct of medical device clinical studies;

  2. To highlight the benefits of engaging with patient advisors early in the medical device development process

  3. To illustrate which patient engagement activities are generally not considered by FDA to constitute research or activity subject to FDA’s regulations, including regulations regarding institutional review boards (IRBs)

  4. To address common questions and misconceptions about collecting and submitting to FDA patient engagement information regarding the design and conduct of a medical device clinical study.

Click HERE to know more detailed information about this guideline.

Comments


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page